325 related articles for article (PubMed ID: 36831330)
1. Sirtuin 6-A Key Regulator of Hepatic Lipid Metabolism and Liver Health.
Dong XC
Cells; 2023 Feb; 12(4):. PubMed ID: 36831330
[TBL] [Abstract][Full Text] [Related]
2. SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1.
Zhu C; Huang M; Kim HG; Chowdhury K; Gao J; Liu S; Wan J; Wei L; Dong XC
Biochim Biophys Acta Mol Basis Dis; 2021 Dec; 1867(12):166249. PubMed ID: 34425214
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation.
Hou T; Tian Y; Cao Z; Zhang J; Feng T; Tao W; Sun H; Wen H; Lu X; Zhu Q; Li M; Lu X; Liu B; Zhao Y; Yang Y; Zhu WG
Mol Cell; 2022 Nov; 82(21):4099-4115.e9. PubMed ID: 36208627
[TBL] [Abstract][Full Text] [Related]
4. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
5. SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate Cells.
Zhong X; Huang M; Kim HG; Zhang Y; Chowdhury K; Cai W; Saxena R; Schwabe RF; Liangpunsakul S; Dong XC
Cell Mol Gastroenterol Hepatol; 2020; 10(2):341-364. PubMed ID: 32305562
[TBL] [Abstract][Full Text] [Related]
6. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
Tao R; Xiong X; DePinho RA; Deng CX; Dong XC
J Biol Chem; 2013 Oct; 288(41):29252-9. PubMed ID: 23974119
[TBL] [Abstract][Full Text] [Related]
7. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
8. SIRT6: therapeutic target for nonalcoholic fatty liver disease.
Zang M; Gao B
Trends Endocrinol Metab; 2022 Dec; 33(12):801-803. PubMed ID: 36328906
[TBL] [Abstract][Full Text] [Related]
9. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
10. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
11. Sirtuin 6 protects against hepatic fibrogenesis by suppressing the YAP and TAZ function.
Chowdhury K; Huang M; Kim HG; Dong XC
FASEB J; 2022 Oct; 36(10):e22529. PubMed ID: 36036554
[TBL] [Abstract][Full Text] [Related]
12. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation.
Purushotham A; Schug TT; Xu Q; Surapureddi S; Guo X; Li X
Cell Metab; 2009 Apr; 9(4):327-38. PubMed ID: 19356714
[TBL] [Abstract][Full Text] [Related]
14. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
15. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
16. A promising therapy for fatty liver disease: PCSK9 inhibitors.
Han L; Wu L; Yin Q; Li L; Zheng X; Du S; Huang X; Bai L; Wang Y; Bian Y
Phytomedicine; 2024 Jun; 128():155505. PubMed ID: 38547616
[TBL] [Abstract][Full Text] [Related]
17. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
[TBL] [Abstract][Full Text] [Related]
18. Fluvastatin activates sirtuin 6 to regulate sterol regulatory element-binding proteins and AMP-activated protein kinase in HepG2 cells.
Kim JH; Lee JM; Kim JH; Kim KR
Biochem Biophys Res Commun; 2018 Sep; 503(3):1415-1421. PubMed ID: 30078674
[TBL] [Abstract][Full Text] [Related]
19. Lycopene and apo-10'-lycopenoic acid have differential mechanisms of protection against hepatic steatosis in β-carotene-9',10'-oxygenase knockout male mice.
Ip BC; Liu C; Lichtenstein AH; von Lintig J; Wang XD
J Nutr; 2015 Feb; 145(2):268-76. PubMed ID: 25644347
[TBL] [Abstract][Full Text] [Related]
20. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
